I research 5-10 companies a week, mostly otc, to trade including a couple of ohm20 listed. Breakout boards, most read, most posted, chart plays, stocktwits, pm recommendations, twitter, news, science publications, etc. That is how I first found cydy 2.5 years ago, it was on the breakout boards on ihub.
Honestly though, I just didn't see the others long term potential, which is why I am still here and not there. I believe we have the potential here to see billions in revenue now. I just don't see that with the others. Originally I traded cydy and was in for a 4x gain once combo was approved, now with mono (which I doubted originally--that is okay though--NP said even Maddon the inventor was surprised), I was thinking 10x, but now we have the cancer potential.
I guess some just see delays, I've seen great progress from 2.5 years ago to now. successful combo p3 trial with part of the bla submitted, mono p3 pivotal trial submitted, tnbc trial starting, gvhd restarting after RP included his great ideas, so much coming.
I guess it would suck to sell for a lose and then have the stock take-off, so seeing cydy succeed might hurt and looking for confirmation of failure by focusing on the ceo or delays helps reaffirm your decision. But I'm here to see it through. With combo approval almost certain and months away (which I'm sure some of the original 50 lives have been saved with it), it seems crazy to me to drop out now, but that is me. Then cancer, ccr5 inhibitors working in many many studies with many types of cancers has given me convinced we will get good results. My strategy is to collect as many shares as possible with as low cost average before it takes off. Anyone catch I believe NP's father in law has prostate cancer and they are working to get the drug through the extended access program. That speaks volumes about NP's belief in the drug. If I had metastatic cancer, I would be pushing very hard to include leronlimab in my treatment.
